<SEC-DOCUMENT>0001628280-17-003253.txt : 20170331
<SEC-HEADER>0001628280-17-003253.hdr.sgml : 20170331
<ACCEPTANCE-DATETIME>20170331172229
ACCESSION NUMBER:		0001628280-17-003253
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170331
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20170331
DATE AS OF CHANGE:		20170331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		17731435

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k-caldolorpressrelease.htm
<DESCRIPTION>8-K - CALDOLOR PRESS RELEASE
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s08c14c1f50254e02aeb0bd4eaa2e3a9d"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):                &#160;                        March 31, 2017 (March 27, 2017)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:0%;"></td><td style="width:39%;"></td><td style="width:28%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:  (615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 27, 2017, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the publication of a trial providing evidence that using Caldolor in multimodal pain control strategies improves postoperative pain control and reduces opioid use in patients undergoing transsphenoidal surgery. A copy of the press release is furnished as Exhibit 99.1.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:61%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><hr></div><div style="line-height:120%;padding-top:15px;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibit&#160;Index </font></div><div style="line-height:120%;padding-top:15px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.5625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:20%;"></td><td style="width:13%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Exhibit No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Press release dated March 27, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease-caldolor.htm
<DESCRIPTION>EXHIBIT 99.1 - PRESS RELEASE CALDOLOR
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s02da6e7b298449a0956267536077a2de"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:32px;padding-top:8px;text-align:center;"><img src="cumberlanda03.gif" alt="cumberlanda03.gif" style="font-size:11pt;height:122px;width:536px;"></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CALDOLOR</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;DEMONSTRATES SIGNIFICANT POST SURGICAL </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PAIN REDUCTION AND DECREASE IN OPIOID USE</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:32px;padding-top:8px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">New study data supports the use of Caldolor</font><font style="font-family:inherit;font-size:11pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#32;in controlling pain and reducing opioid use in surgical patients.</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NASHVILLE, Tenn. (Monday, March 27, 2017)</font><font style="font-family:inherit;font-size:10pt;">&#32;- Cumberland Pharmaceuticals Inc. </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(NASDAQ: CPIX)</font><font style="font-family:inherit;font-size:10pt;">&#32;today announced the publication of a trial providing evidence that using Caldolor in multimodal pain control strategies improves postoperative pain control and reduces opioid use in patients undergoing transsphenoidal surgery. The trial was conducted at the Department of Neurosurgery, Barrow Neurological Institute, St. Joseph&#8217;s Hospital and Medical Center in Phoenix, Arizona and was published in the </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Journal of Neurosurgery</font><font style="font-family:inherit;font-size:10pt;">, March 2017. </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8220;The United States is in the midst of an epidemic of excessive opioid use, misuse, and abuse to control chronic pain,&#8221; said AJ Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. &#8220;The more we can prevent postsurgical pain from transitioning into chronic pain, the more likely we are to decrease reliance on opioids and improve the quality of life for patients long-term. We are thrilled to add this study to the growing body of literature supporting the safety and use of Caldolor in hospitalized patients.&#8221; </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trial compared outcomes in 2 groups of patients treated with multimodal pain management protocols following transsphenoidal surgery for pituitary lesions: Group 1 patients treated intraoperatively with IV Ibuprofen (Caldolor 800 mg q 8 hr), scheduled oral acetaminophen and rescue opioids, versus Group 2 patients treated with IV saline placebo q 8 hr, scheduled oral acetaminophen, and rescue opioids. The Caldolor Group 1 patients demonstrated a significant reduction of 43% mean VAS scores compared with Placebo Group 2 patients.  Opioid use was also significantly different, with a 58% reduction in the Caldolor Group 1 patients compared to Placebo Group 2 patients.  </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The study had two aims.  The primary endpoint was patient pain scores measured on a 0-10 Visual Analog Scale (VAS), and the secondary endpoint was the estimated oral morphine equivalent (OME) used for breakthrough pain in the first 48 hours after surgery.  The study was terminated early because the planned interim analysis demonstrated that the primary and secondary endpoints had been reached.  </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Caldolor</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup>&#160;</font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Caldolor is indicated in adults and pediatric patients six months and older for the management of mild to moderate pain and the management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever.  It was the first FDA approved intravenous therapy for fever.  Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with a history of asthma or other allergic-type reactions after taking aspirin or other NSAIDs.  Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery.  Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors.  Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit </font><font style="font-family:inherit;font-size:10pt;color:#0000ff;text-decoration:underline;">www.caldolor.com</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">About Cumberland Pharmaceuticals</font></div><div style="line-height:174%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.&#160;is a specialty pharmaceutical company focused on acquisition, development, and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's six marketed products include Acetadote</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">acetylcysteine</font><font style="font-family:inherit;font-size:10pt;">) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ibuprofen</font><font style="font-family:inherit;font-size:10pt;">) Injection, for the treatment of pain and fever, Kristalose</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">lactulose</font><font style="font-family:inherit;font-size:10pt;">) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">conivaptan</font><font style="font-family:inherit;font-size:10pt;">) Injection, for the treatment of hyponatremia, Omeclamox-Pak</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;for the treatment of&#160;H. pylori</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font><font style="font-family:inherit;font-size:10pt;">infection and duodenal ulcer disease, and Ethyol</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">amifostine</font><font style="font-family:inherit;font-size:10pt;">) for Injection, for the treatment of oncology patients. Cumberland is developing Hepatoren</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:10pt;">) Injection for the treatment of Hepatorenal Syndrome, Boxaban</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:10pt;">) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, Vasculan</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">&#160;(</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">ifetroban</font><font style="font-family:inherit;font-size:10pt;">) Oral Capsule for the treatment of Systemic Sclerosis, and Portaban</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:inherit;font-size:10pt;">, for the treatment of Portal Hypertension. </font></div><div style="line-height:174%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlanda03.gif
<TEXT>
begin 644 cumberlanda03.gif
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M.N0GG3[<XBNI?IO?*;G>*7.FMVZ[2K)#"3OK:/%-%8/E)GF=9YY5![(//C0
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M)R.J$RZ:!BN_@A.7I=PUV7G!5[(O(ZY(JV7*/+*E.&)<Z'2B0U-6/LD'UG6
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ME2^9>,>YLYK0/  (_MQN &PB]#LJV-LD#!AXQ2].C2F8) 0]X-P!0D"2+/M
M ]"KH (.,(4Y/[E3J6ASM:O]9C=S8!I0U\<!R! MEP2!'P8X1=;W88!]<-WK
M!A  UT\A]GW3!0("$$ ">J#3#9!= %/J']K3SH/(A*0  @B[ #8@K#&D_>M>
M!WS7 Y_U1@5;*P7 >M?#/OC&@WT?9!\55_ ^=LCO(^^6)_SE3\%WM?0C5 (
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M *<P!H!P@W"7+X82@R@G@>*',"'A=_Q7$L7(%6C3D0^0BA+H!=/A!=+H %0
M!!L@#S"Y0R+Q "-##=FX$HC&3%<(9VYV;>C89J3@?>U("M?V ZE -"#D$:&8
M #18$O(0*@G  PO&A*X'DB6Q 7I'>PPR=U20B!<80#R0=QK0@ !W*LSXBE59
M$@[@>I6(%?48<<T!')0G?R$1E-JQ?TD( "9)D=%E7^I"@@$)D )0B?_"%7;)
M=8E9>+ZX-6/0=7$7;5Q!E*=PF"5!B ; #[37#\='#1MP  6 E.1!*&CA  A@
M#S4B%Y9"4.)PCLK9_Y73\'0_ '7>]V8'\ -30%,R-649Z'HT^(L>P3G/-Q(
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MRZ&WXV[SEVKWGZV7[.2;TWT]>R;QRST/=JXG]*'' )\HB&6=*IM1'2R%"E,
M =2B:VKA7_E9AO(&WM %$EBN%QC2 Y\#!+ZD"PCP^(Y?;KXD?%Q/W%3@2XS/
M^)#_^)D_!L*7V#JM+1I@W;$Q!4#  PB D2%!;H_?^K[T^)B/^9#*GXUJ;K'O
M^IH_^0APNA@HB:=;&H]S'4M9;@B0_Y.2,SV1K_F=KRV;+]A0K"V3?K2M<:SF
M9JE^6FY 8/Q0@C:2" 08^+JVS_FWO_N0FL8M<1I+3B^BG H'H/?*3>I_;QS
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M^#J0P\8Z LI#K?1Z#\.?M&H.1-,HFH^\@7P0![>Y])/@!_XXF";)$:;11Q\
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M'QO'  0!*/%H&.,E/<S'QU^^#B$%2$ "#C C+T23"FD+S10$D !J.$N634S
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EENT,R5'!1LVO-'5DG#8]));2UFF4$%Y62XV/G4S60/F'@   .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
